Yes, I caught that brief segment on the webcast. As Wheeler said, MNTA is not running a safety-and-efficacy trial in support of its Copaxone ANDA, nor will it be required to do so as far as the company knows.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.